These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 20854749)

  • 41. Cognitive Go/No-Go decision-making criteria in Alzheimer's disease drug development.
    Wessels AM; Edgar CJ; Nathan PJ; Siemers ER; Maruff P; Harrison J
    Drug Discov Today; 2021 May; 26(5):1330-1336. PubMed ID: 33486115
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.
    Dubois B; Feldman HH; Jacova C; Hampel H; Molinuevo JL; Blennow K; DeKosky ST; Gauthier S; Selkoe D; Bateman R; Cappa S; Crutch S; Engelborghs S; Frisoni GB; Fox NC; Galasko D; Habert MO; Jicha GA; Nordberg A; Pasquier F; Rabinovici G; Robert P; Rowe C; Salloway S; Sarazin M; Epelbaum S; de Souza LC; Vellas B; Visser PJ; Schneider L; Stern Y; Scheltens P; Cummings JL
    Lancet Neurol; 2014 Jun; 13(6):614-29. PubMed ID: 24849862
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Perspectives on episodic-like and episodic memory.
    Pause BM; Zlomuzica A; Kinugawa K; Mariani J; Pietrowsky R; Dere E
    Front Behav Neurosci; 2013; 7():33. PubMed ID: 23616754
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimizing phase II of drug development for disease-modifying compounds.
    Cummings JL
    Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S15-20. PubMed ID: 18631992
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevention trials in Alzheimer's disease: an EU-US task force report.
    Vellas B; Aisen PS; Sampaio C; Carrillo M; Scheltens P; Scherrer B; Frisoni GB; Weiner M; Schneider L; Gauthier S; Gispen-de Wied CC; Hendrix S; Feldman H; Cedarbaum J; Petersen R; Siemers E; Andrieu S; Prvulovic D; Touchon J; Hampel H
    Prog Neurobiol; 2011 Dec; 95(4):594-600. PubMed ID: 21925234
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).
    Roses AD; Saunders AM; Huang Y; Strum J; Weisgraber KH; Mahley RW
    Pharmacogenomics J; 2007 Feb; 7(1):10-28. PubMed ID: 16770341
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Relevance of the evaluation criteria used in clinical trials for Alzheimer's disease.
    Truffinet P; Bordet R; Ménard J
    Therapie; 2009; 64(3):139-8. PubMed ID: 19671425
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biomarkers for the early stages of clinical development in Alzheimer's disease.
    Bordet R; Dartigues JF; Dubois B; Goehrs JM; Vernoux L; Semah F; Pasquier F; Bidaut-Mazel C;
    Therapie; 2010; 65(4):285-90, 277-283. PubMed ID: 20854749
    [TBL] [Abstract][Full Text] [Related]  

  • 49.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 50.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.